BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

679 related articles for article (PubMed ID: 29699516)

  • 1. Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells.
    Morrison BJ; Steel JC; Morris JC
    BMC Cancer; 2018 Apr; 18(1):469. PubMed ID: 29699516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules.
    Tallerico R; Todaro M; Di Franco S; Maccalli C; Garofalo C; Sottile R; Palmieri C; Tirinato L; Pangigadde PN; La Rocca R; Mandelboim O; Stassi G; Di Fabrizio E; Parmiani G; Moretta A; Dieli F; Kärre K; Carbone E
    J Immunol; 2013 Mar; 190(5):2381-90. PubMed ID: 23345327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based-vaccine in a Hu-PBL-SCID mouse model.
    Lu Y; Zhang Z; Liu Q; Liu B; Song X; Wang M; Zhao X; Zhao Q
    Biol Pharm Bull; 2007 Jan; 30(1):150-6. PubMed ID: 17202676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.
    Mikysková R; Bubeník J; Vonka V; Smahel M; Indrova M; Bieblová J; Símová J; Jandlová T
    Int J Oncol; 2005 Feb; 26(2):521-7. PubMed ID: 15645139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flagellin enhances tumor-specific CD8⁺ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model.
    Nguyen CT; Hong SH; Sin JI; Vu HV; Jeong K; Cho KO; Uematsu S; Akira S; Lee SE; Rhee JH
    Vaccine; 2013 Aug; 31(37):3879-87. PubMed ID: 23831323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sphere culture of murine lung cancer cell lines are enriched with cancer initiating cells.
    Morrison BJ; Steel JC; Morris JC
    PLoS One; 2012; 7(11):e49752. PubMed ID: 23152931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
    Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
    Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptively transferred human lung tumor specific cytotoxic T cells can control autologous tumor growth and shape tumor phenotype in a SCID mouse xenograft model.
    Oflazoglu E; Elliott M; Takita H; Ferrone S; Henderson RA; Repasky EA
    J Transl Med; 2007 Jun; 5():29. PubMed ID: 17592641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope.
    Huang CH; Peng S; He L; Tsai YC; Boyd DA; Hansen TH; Wu TC; Hung CF
    Gene Ther; 2005 Aug; 12(15):1180-6. PubMed ID: 15800656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4.
    Volonté A; Di Tomaso T; Spinelli M; Todaro M; Sanvito F; Albarello L; Bissolati M; Ghirardelli L; Orsenigo E; Ferrone S; Doglioni C; Stassi G; Dellabona P; Staudacher C; Parmiani G; Maccalli C
    J Immunol; 2014 Jan; 192(1):523-32. PubMed ID: 24277698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways.
    Cheng WF; Hung CF; Lee CN; Su YN; Chang MC; He L; Wu TC; Chen CA; Hsieh CY
    Eur J Immunol; 2004 Jul; 34(7):1892-900. PubMed ID: 15214037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
    Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
    Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility to cytotoxic T cell lysis of cancer stem cells derived from cervical and head and neck tumor cell lines.
    Liao T; Kaufmann AM; Qian X; Sangvatanakul V; Chen C; Kube T; Zhang G; Albers AE
    J Cancer Res Clin Oncol; 2013 Jan; 139(1):159-70. PubMed ID: 23001491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope.
    Morishima S; Akatsuka Y; Nawa A; Kondo E; Kiyono T; Torikai H; Nakanishi T; Ito Y; Tsujimura K; Iwata K; Ito K; Kodera Y; Morishima Y; Kuzushima K; Takahashi T
    Int J Cancer; 2007 Feb; 120(3):594-604. PubMed ID: 17096336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-replicating Newcastle Disease Virus as an adjuvant for DNA vaccine enhances antitumor efficacy through the induction of TRAIL and granzyme B expression.
    Mohebbi A; Ebrahimzadeh MS; Baghban Rahimi S; Saeidi M; Tabarraei A; Mohebbi SR; Shirian S; Gorji A; Ghaemi A
    Virus Res; 2019 Feb; 261():72-80. PubMed ID: 30599161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Codon optimized expression of HPV 16 E6 renders target cells susceptible to E6-specific CTL recognition.
    Samorski R; Gissmann L; Osen W
    Immunol Lett; 2006 Sep; 107(1):41-9. PubMed ID: 16949679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes.
    Seliger B; Harders C; Wollscheid U; Staege MS; Reske-Kunz AB; Huber C
    Exp Hematol; 1996 Sep; 24(11):1275-9. PubMed ID: 8862437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
    Maccalli C; Parmiani G; Ferrone S
    Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.
    Neeley YC; McDonagh KT; Overwijk WW; Restifo NP; Sanda MG
    Prostate; 2002 Nov; 53(3):183-91. PubMed ID: 12386918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.